Sanofi India Limited

NSE SANOFI.NS

Sanofi India Limited EBIT for the year ending December 31, 2023: USD 101.77 M

Sanofi India Limited EBIT is USD 101.77 M for the year ending December 31, 2023, a -2.67% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Sanofi India Limited EBIT for the year ending December 31, 2022 was USD 104.56 M, a -38.12% change year over year.
Sanofi India Limited EBIT for the year ending December 31, 2021 was USD 168.96 M, a 81.81% change year over year.
Sanofi India Limited EBIT for the year ending December 31, 2020 was USD 92.93 M, a 10.73% change year over year.
Sanofi India Limited EBIT for the year ending December 31, 2019 was USD 83.93 M, a -4.09% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NSE: SANOFI.NS

Sanofi India Limited

CEO	Mr. Rodolfo Hrosz
IPO Date	July 1, 2002
Location	India
Headquarters	Sanofi House
Employees	2,174
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singaporem and internationally. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, epilepsy, allergy and vitamins, anti-histamines, and minerals and supplements under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. The company also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

Key trends

Past 5 years